Keyword: Opdivo

opdivo

6. Opdivo

2019 was something of an annus horribilis when it came to trying to find new therapies for aggressive brain cancer glioblastoma multiforme, and one of the biggest disappointments came from the failure of an immuno-oncology approach to the disease.
Fail sign

2019’s top 15 clinical trial flops (and a flip-flop)

This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.